Sign In

Jack Scannell

CEO, Etheros Pharmaceuticals Corp.

Jack Scannell is the Chief Executive Officer of Etheros Pharmaceuticals, a position he has held since October 2021. Based in Delaware, United States, Scannell is known for his focus on "predictive validity" in drug research and development (R&D), emphasizing its importance for improving the drug development process.

Professional Background

  • Founder of JW Scannell Analytics Ltd.: Since August 2014, he has been involved in analytics related to drug development.

  • Honorary Fellow: He is associated with the School of Social and Political Science at the University of Edinburgh, contributing to research on the influences of regulation and economics on R&D for new antimicrobial drugs and diagnostics.

  • Previous Roles:

    • Co-head of Pharmaceuticals - Equity Research at UBS (2016-2019): Focused on European drug and biotech stocks.
    • Head of Discovery Research at e-Therapeutics PLC (2013-2014): Engaged in early-stage drug discovery.
    • Management Consultant at Boston Consulting Group (2000-2005).
    • University Lecturer at Newcastle University (1995-1999): Specialized in systems neuroscience and mathematical biology.

Scannell's extensive experience in pharmaceuticals and biotechnology, combined with his academic involvement, positions him as a significant figure in the industry, particularly in discussions around drug R&D productivity and innovation.1

Related Questions

What is predictive validity in drug R&D?
How did Jack Scannell transition from equity analysis to pharmaceuticals?
What are the main challenges in drug R&D productivity?
What is JW Scannell Analytics LTD?
How does Jack Scannell's work at Etheros Pharmaceuticals impact drug discovery?
Jack Scannell
Jack Scannell, photo 1
Jack Scannell, photo 2
Add to my network

Experience

Chief Executive Officer at Etheros Pharmaceuticals - October 2021 to Present
Founder of JW Scannell Analytis LTD - August 2014 to Present, Honorary Fellow at the School of Social and Political Science & Innogen Associate, The University of Edinburgh - September 2014 to Present, Co-head of Pharmaceuticals - Equity Research at UBS - June 2016 to October 2019

Location

Edinburgh, Scotland, United Kingdom